Future Proof Health Limited
Unaudited Financial Statements
For the year ended 31 August 2024
Pages for Filing with Registrar
Company Registration No. 09185062 (England and Wales)
Future Proof Health Limited
Company Information
Directors
Dr K Dawes
J L Jones
(Appointed 1 July 2024)
Dr S Vishram
(Appointed 1 July 2024)
R L Clarke
(Appointed 1 July 2024)
Secretary
B J Wakelam
Company number
09185062
Registered office
175 The Ridgeway Surgery
Dudley
West Midlands
England
DY3 3UH
Accountants
Moore Kingston Smith LLP
Orbital House
20 Eastern Road
Romford
Essex
RM1 3PJ
Future Proof Health Limited
Contents
Page
Balance sheet
1
Notes to the financial statements
2 - 4
Future Proof Health Limited
Balance Sheet
As at 31 August 2024
Page 1
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
Current assets
Debtors
4
28,947
39,220
Cash at bank and in hand
53,758
63,711
82,705
102,931
Creditors: amounts falling due within one year
5
(116,594)
(87,759)
Net current (liabilities)/assets
(33,889)
15,172
Capital and reserves
Called up share capital
6
170,933
170,933
Profit and loss reserves
(204,822)
(155,761)
Total equity
(33,889)
15,172
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
For the financial year ended 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the board of directors and authorised for issue on 6 January 2025 and are signed on its behalf by:
Dr K Dawes
Director
Company Registration No. 09185062
Future Proof Health Limited
Notes to the Financial Statements
For the year ended 31 August 2024
Page 2
1
Accounting policies
Company information
Future Proof Health Limited is a private company limited by shares incorporated in England and Wales. The registered office is 175 The Ridgeway Surgery, Dudley, West Midlands, England, DY3 3UH.
1.1
Accounting convention
These financial statements have been prepared in accordance with Section 1A of FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Going concern
At the balance sheet date the company had net trueliabilities of £33,889 (2023: net assets of £15,172) following a loss for the year at £49,061 (2023: profit £26,494). At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and for a period of at least twelve months following the approval of these financial statements. The directors have confirmed that they will continue to support the company for a period of at least 12 months from the date of signing to enable it to meet its liabilities as they fall due. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for health care services provided in the normal course of business.
1.4
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Computer equipment
25% straight line
1.5
Cash and cash equivalents
Cash at bank and in hand are basic financial assets and include cash in hand and deposits held at call with banks.
1.6
Financial instruments
All of the company's financial assets and liabilities are basic and measured at amortised cost.
Future Proof Health Limited
Notes to the Financial Statements (Continued)
For the year ended 31 August 2024
Page 3
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was 14 (2023: 13)
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 September 2023
1,399
Disposals
(350)
At 31 August 2024
1,049
Depreciation and impairment
At 1 September 2023
1,399
Eliminated in respect of disposals
(350)
At 31 August 2024
1,049
Carrying amount
At 31 August 2024
At 31 August 2023
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Other debtors
3,024
664
Prepayments and accrued income
25,923
38,556
28,947
39,220
5
Creditors: amounts falling due within one year
2024
2023
£
£
Taxation and social security
1,925
Other creditors
271
2,193
Accruals and deferred income
116,323
83,641
116,594
87,759
Future Proof Health Limited
Notes to the Financial Statements (Continued)
For the year ended 31 August 2024
Page 4
6
Called up share capital
2024
2023
£
£
Ordinary share capital
46 Ordinary A shares of 1p each
1
1
310,786 Ordinary B shares of 55p each
170,932
170,932
170,933
170,933
The 46 ordinary 'A' shares with a nominal value of 1p each carry voting rights but no dividend rights.
The 310,786 ordinary 'B' shares with a nominal value of 55p each carry no voting rights but have full dividend rights.
On winding up the 'A' shares carry preferential rights to a distribution.
7
Related party transactions
During the year consultancy services were charged by the directors of £40,400 (2023: £27,750). Included in other creditors are amounts due to the directors of £52,200 (2023: £14,300).